Kiora Pharmaceuticals

Kiora Pharmaceuticals

Pharmaceuticals
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.

$3.2M

Market Cap • 11/20/2026

1998

(28 years)

Founded

2015

(11 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

0,2

P/S

—

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

3,5

EPS

—

Market Cap

Market Cap

3,2M

EV

-12,8M

EV/Revenue

—

EV/EBITDA

0,9

EV/EBIT

0,9

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-154,7%

Total Yield

-154,7%

Payout

0%

Retained Earnings

-160,5M

Profitability

Gross Margin

—

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

0%

Capex/Revenue

0%

Capex/D&A

243,4%

Capex/OCF

-1,4%

SBC/OCF

—

% PPE

1,4%

% Goodwill

0%

ROE

—

ROIC

—

Growth

CAGR Op. Income 5Y

8,7%

CAGR Net Income 5Y

7,8%

CAGR EPS 5Y

-63,1%

CAGR OCF 5Y

78,9%

Leverage

N.D./EBITDA

1,2

Debt/Equity

0%

Current Ratio

7,9

Quick Ratio

7,3

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium